All articles tagged with #viking therapeutics
Viking Therapeutics stock surged nearly 38% after data showed its obesity drug VK2735 maintained up to 97% of weight loss when dosing frequency was reduced, strengthening its competitive position against Eli Lilly and Novo Nordisk.
Vertex’s about $10 billion Crinetics acquisition has rekindled takeover chatter in the obesity-drug space, putting Viking Therapeutics (VKTX) in the spotlight as a potential target. Viking’s VK2735 is advancing in the late-stage VANQUISH trials with injectable and planned oral forms, while VK3019 has entered Phase 1, adding a second asset targeting obesity and metabolic disorders. Although attractive to large pharma seeking diversified portfolios, Viking remains a clinical-stage company with no revenue, so any deal would depend on forthcoming VK2735 and VK3019 data and the company’s cash runway.
Viking Therapeutics experienced its worst stock decline on record, leading short sellers to profit $521 million, after a mid-stage study of its obesity pill showed significant side effects, undermining investor confidence despite analyst optimism and high price targets.
Viking Therapeutics' oral weight loss drug VK2735 showed promising weight reduction in a Phase 2 trial, but high rates of gastrointestinal side effects and discontinuation have disappointed investors.
Viking Therapeutics' shares plummeted by about 43% after disappointing midstage trial results for its obesity pill, which showed less favorable weight loss and higher side effects compared to competitors like Eli Lilly and Novo Nordisk, potentially limiting its future in the obesity drug market.
Viking Therapeutics' stock plummeted 40% after a Phase 2 trial showed its oral weight-loss drug, VK2735, was effective but had high discontinuation rates and side effects, raising concerns among investors about its tolerability and efficacy compared to competitors like Eli Lilly.
Viking Therapeutics' stock plummeted over 35% after mixed results from its weight-loss drug, which showed significant weight loss but also a high dropout rate due to side effects, leading to investor concern and a sharp decline in share price.
Viking Therapeutics' stock dropped 37% after revealing that its obesity drug VK2735 had a high dropout rate in a Phase 2 trial, despite showing some efficacy in weight loss. The high discontinuation rate raised concerns about the drug's tolerability and competitive position compared to Eli Lilly's offerings, leading to investor skepticism about Viking's prospects in the oral obesity market.
Viking Therapeutics announced positive top-line results from a Phase 2 trial of VK2735, an oral tablet for obesity, showing significant weight loss up to 12.2% over 13 weeks, with good safety and tolerability, supporting further development for metabolic disorders.
With Donald Trump returning to the presidency and Republicans controlling Congress, a less stringent regulatory environment could lead to a surge in mergers and acquisitions (M&A). Factors like recent interest rate cuts and potential changes in the Federal Trade Commission's leadership could further encourage M&A activity. Viking Therapeutics, a clinical-stage pharmaceutical company with promising obesity treatments, is highlighted as a potential acquisition target, though any such deals remain speculative.
Viking Therapeutics' stock surged over 25% after reporting positive Phase 1 results for its oral weight-loss drug, showing up to 5.3% weight loss in patients with minimal side effects. The company plans to launch the drug into Phase 2 trials later this year, following strong results from its injectable version. Analysts view the data as a "clear win" and believe the drug has best-in-class potential, positioning it to compete with current market leaders in the weight-loss drug space.
Viking Therapeutics stock surged by 25% after announcing positive results from a phase 1 clinical study of its oral obesity drug VK2735, showing up to 3.3% placebo-adjusted mean weight loss and promising safety and tolerability. The company plans to advance the oral and injectable formulations of the drug into further testing, with expectations for strong pipeline prospects, making it a potential buy for aggressive investors.
Viking Therapeutics' experimental weight-loss tablet, VK2735, showed promising results in a small early-stage trial, with the highest 40-milligram dose leading to a 3.3% weight loss in participants. The company's shares rose 15% following the news. Viking plans to continue testing higher doses and expects to initiate a mid-stage study in obese patients later this year. The drug's oral version could offer a more convenient option for patients, especially those who have achieved significant weight loss with the injectable version.
Viking Therapeutics' stock surged over 15% after positive results from a small study on its experimental weight loss pill, which is set to enter the next stage of development later this year. The once-a-day oral tablet showed promising results in reducing weight, with patients losing up to 5.3% of their weight on average. The company plans to start a phase two trial for the pill and believes that treating patients beyond 28 days may lead to further reductions in body weight. Analysts view Viking as a strong potential player in the burgeoning weight loss drug market, which could grow into a $100 billion market by the end of the decade.
Viking Therapeutics announces positive results from a Phase 1 clinical trial of VK2735, a dual GLP-1/GIP receptor agonist, showing up to 3.3% placebo-adjusted mean weight loss and low rates of gastrointestinal adverse events after 28 days of oral tablet formulation. The company plans to initiate a Phase 2 trial in obesity later this year and will host a conference call to discuss the results. VK2735 demonstrated promising early weight loss and tolerability, with potential for additional weight loss with longer treatment duration and higher doses.